Indeed, their CD30 expression is a main diagnostic marker (6), and is nowadays also of therapeutic relevance, as treatment of HL patients with a toxin-conjugated anti-CD30 antibody (Brentuximab vedotin) is a promising targeted treatment approach at relapse (7). This evidence concerns the gene TNFRSF8 and Hodgkins lymphoma.